The price of Blueprint Medicines Corp (NASDAQ:BPMC) shares last traded on Wall Street rose 0.41% to $102.81.
BPMC stock price is now 7.69% away from the 50-day moving average and 37.42% away from the 200-day moving average. The market capitalization of the company currently stands at $6.44B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $140, Stephens recently initiated with Overweight rating for Blueprint Medicines Corp (NASDAQ: BPMC). On May 06, 2024, Leerink Partners Upgraded its previous ‘Underperform’ rating to ‘Market Perform’ on the stock increasing its target price from $50 to quote $97, while ‘Oppenheimer’ rates the stock as ‘Outperform’
In other news, Hurley Ariel, PRINCIPAL ACCOUNTING OFFICER sold 5,856 shares of the company’s stock on May 15 ’24. The stock was sold for $626,379 at an average price of $106.96. Upon completion of the transaction, the PRINCIPAL ACCOUNTING OFFICER now directly owns 14,913 shares in the company, valued at $1.53 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 15 ’24, CHIEF FINANCIAL OFFICER Landsittel Michael sold 3,850 shares of the business’s stock. A total of $411,772 was realized by selling the stock at an average price of $106.95. This leaves the insider owning 71,617 shares of the company worth $7.36 million. A total of 2.08% of the company’s stock is owned by insiders.
During the past 12 months, Blueprint Medicines Corp has had a low of $43.89 and a high of $111.02. As of last week, the company has a debt-to-equity ratio of 1.92, a current ratio of 3.76, and a quick ratio of 3.61. The fifty day moving average price for BPMC is $95.771 and a two-hundred day moving average price translates $75.09015 for the stock.
The latest earnings results from Blueprint Medicines Corp (NASDAQ: BPMC) was released for 2024-03-31. The net profit margin was -102.15% and return on equity was -79.53% for BPMC. The company reported revenue of $96.12 million for the quarter, compared to $63.29 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 51.87 percent.
